Amgen (AMGN): Price Target and June Short Interest Disclosure

Amgen (AMGN) stock is expected to deviate a maximum of $12.06 from the average target price of $182.23 for the short term period. 13 Street Experts have initiated coverage on the stock with the most promising target being $198 and the most muted being $157.

Amgen (AMGN) has seen a rise of 605,180 shares or 8.4% in the short interest. The remaining shorts are 1% of the total floated shares. The net short interest, as on June 30,2016, stood at 7,802,478 shares and the stocks days to cover will be 2 by factoring in the average per day volume of 3,769,661 shares. On June 15,2016, 7,197,298 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Bernstein initiates coverage on Amgen (NASDAQ:AMGN). Bernstein has a Market Perform rating on the shares. The rating by the firm was issued on June 29, 2016.


Amgen (NASDAQ:AMGN): stock turned positive on Thursday. Though the stock opened at $162, the bulls momentum made the stock top out at $162.99 level for the day. The stock recorded a low of $160.74 and closed the trading day at $162.74, in the green by 1.38%. The total traded volume for the day was 2,444,804. The stock had closed at $160.52 in the previous days trading.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.